BACK

AstraZeneca vaccine provisionally approved for NZ – Expert Reaction

This article was published on
July 29, 2021

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.

New Zealand’s medicines regulator Medsafe has given the provisional green light to the AstraZeneca vaccine, making it the third Covid-19 vaccine approved for use among NZ’s adult population. The viral vector vaccine is one of four purchase agreements the government has made with pharmaceutical companies. Associate Health Minister Dr Ayesha Verrall said the country’s immunisation plan remains focused on rolling out the Pfizer mRNA vaccine.

New Zealand’s medicines regulator Medsafe has given the provisional green light to the AstraZeneca vaccine, making it the third Covid-19 vaccine approved for use among NZ’s adult population. The viral vector vaccine is one of four purchase agreements the government has made with pharmaceutical companies. Associate Health Minister Dr Ayesha Verrall said the country’s immunisation plan remains focused on rolling out the Pfizer mRNA vaccine.

Publication

What our experts say

Context and background

Resources

Media briefing

Media Release

Expert Comments: 

Dr Rawiri McKree Jansen (Ngati Raukawa, Ngati Hinerangi)

AstraZeneca vaccine approval gives New Zealand additional opportunities to ramp up our vaccination programme. The vaccine might be especially useful for some specific population cohorts and thus give us greater population coverage. Consideration should include the opportunity for AstraZeneca-Pfizer ‘mix and match’ regimes.

Professor David Murdoch

The approval of the AstraZeneca vaccine gives us more options in the future. The focus is still on using the Pfizer vaccine, but the provisional approval of the AstraZeneca vaccine gives us greater flexibility.

Q&A

No items found.